Innovative diagnostic modalities such as next-generation sequencing (NGS) have facilitated the identification of recurrent genetic mutations, providing valuable prognostic information and guiding treatment decisions. Additionally, the development of novel therapeutic agents, including hypomethylating agents and targeted therapies, has expanded treatment options for MDS patients, improving outcomes and quality of life.
|